You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK):啟動倍諾達®用於一線治療高風險大B細胞淋巴瘤的臨牀研究
格隆匯 03-08 17:03

格隆匯3月8日丨藥明巨諾-B(02126.HK)宣佈已啟動倍諾®(“瑞基奧侖賽注射液”)用於一線治療高風險大B細胞淋巴瘤的臨牀研究,並已完成首例患者的回輸治療。

根據披露,在關鍵性臨牀研究(RELIANCE研究)中,倍諾達®在至少接受過二線治療的複發性╱難治性大B細胞淋巴瘤患者中展現了良好的安全性和出色的療效。這些令人鼓舞的結果將推動CAR-T治療在高風險大B細胞淋巴瘤的前線治療中的應用。該研究是一項在中國進行的開放、單臂、多中心的、研究者發起的試驗(IIT),旨在評估倍諾達®一線治療高風險大B細胞淋巴瘤成人受試者的有效性和安全性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account